Edgewise Therapeutics, Inc. (EWTX) Financials
EWTX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 340.0 million | 21.2 million |
2023-09-30 | 311.4 million | 20.9 million |
2023-06-30 | 330.6 million | 19.2 million |
2023-03-31 | 346.4 million | 17.6 million |
EWTX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -27.0 million | 5.2 million |
2023-09-30 | -22.5 million | 4.6 million |
2023-06-30 | -21.0 million | 4.0 million |
2023-03-31 | -27.2 million | 3.8 million |
EWTX Net Income
No data available :(
EWTX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 318.4 million | - | 5.4 million |
2023-09-30 | 289.7 million | - | 5.5 million |
2023-06-30 | 309.9 million | - | 5.6 million |
2023-03-31 | 328.0 million | - | 5.6 million |
EWTX Shares Outstanding
EWTX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 161000 | 27.7 million | 6.2 million | - |
2023-09-30 | 457000 | 23.8 million | 5.7 million | - |
2023-06-30 | 759000 | 19.6 million | 5.8 million | - |
2023-03-31 | 4.4 million | 19.9 million | 5.8 million | - |
EWTX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | - | 533000 |
2023-09-30 | - | 448000 |
2023-06-30 | - | 437000 |
2023-03-31 | - | 241000 |
EWTX
Price: $17.13
52 week price:
Earnings Per Share: -1.54 USD
P/E Ratio: -14.02
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 74985
Market Capitalization: 1.7 billion